3-iodobenzylguanidine has been researched along with Sclerosis, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, M; Hasegawa, M; Kawano, M; Nakajima, K; Takehara, K; Taki, J; Tonami, N | 1 |
| Gürtner, C; Holzmann, H; Hör, G; Krause, BJ; Wendt, T; Werner, RJ; Winten, G | 1 |
2 other study(ies) available for 3-iodobenzylguanidine and Sclerosis, Systemic
| Article | Year |
|---|---|
Myocardial damages in systemic sclerosis detected by gated myocardial perfusion SPECT and sympathetic imaging.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Diastole; Female; Heart; Heart Diseases; Humans; Male; Middle Aged; Myocardium; Radiopharmaceuticals; Scleroderma, Systemic; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2006 |
Early diagnosis of cardiac involvement in systemic sclerosis by 123I-MIBG neurotransmitter scintigraphy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Arrhythmias, Cardiac; Biological Transport; Female; Heart; Humans; Male; Middle Aged; Myocardium; Prognosis; Radiopharmaceuticals; Raynaud Disease; Scleroderma, Systemic; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 1998 |